learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Search
forLearn
5 / 26 resultslearn GT20029
research compound made to degrade androgen receptors in scalp
learn Hair Multiplication
extract, clone, and reinsert your own hair cells
learn Overview
learn Stemoxydine
chemical from L'Oreal that encourages hair to enter growth phase
Research
5 / 1000+ results
research The Effect of Topical Minoxidil Treatment on Follicular Sulfotransferase Enzymatic Activity
Topical minoxidil does not change the activity of hair follicle enzymes that metabolize it.
research Cytochrome P450: A Target for Drug Development for Skin Diseases
Modulating Cytochrome P450 activity could help develop new skin disease treatments.
research Xenobiotic-Metabolizing Enzymes in the Skin of Rat, Mouse, Pig, Guinea Pig, Man, and in Human Skin Models
Different species and human skin models vary in their skin enzyme activities, with pig skin and some models closely matching human skin, useful for safety assessments and understanding the skin's protective roles.
research Low-Dose Daily Aspirin Reduces Topical Minoxidil Efficacy in Androgenetic Alopecia Patients
Daily low-dose aspirin lowers minoxidil's effectiveness for hair loss treatment.
research The Effect of Active Hexose Correlated Compound in Modulating Cytosine Arabinoside-Induced Hair Loss, and 6-Mercaptopurine- and Methotrexate-Induced Liver Injury in Rodents
AHCC reduces hair loss and liver injury caused by chemotherapy in rodents.
Community Join
5 / 1000+ resultscommunity Phase II Clinical Trial for TDM-105795 started recruiting
A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community GT20029 phase II results release date?
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.